The activation of the NRLP3‐inflammasome has lately been reported as a central pathogenic contributor to neurodegenerative diseases (Voet et al, 2019), including AD (Heneka et al, 2013; Venegas et al, 2017; Ising et al, 2019) and PD (Mao et al, 2017; Lee et al, 2018), further indicating that SGK1 inhibition in glia could be a therapeutic intervention for those disorders. This evidence concerns the gene SGK1 and neurodegenerative disease.